A/Prof Winnie Lam | Singapore General Hospital

Assoc Prof Winnie Lam Wing Chuen
Head ＆ Senior Consultant
Nuclear Medicine and Molecular Imaging
Singapore General Hospital

With over a decade of specialist experience, Winnie has actively contributed to the development of novel PET imaging applications across oncology, neuroimaging, and systemic inflammatory diseases. Her leadership in education, as the inaugural Program Director of the Singapore Nuclear Medicine Residency, and her long-standing service on national training and advisory committees highlight her influence in shaping the next generation of imaging specialists. Winnie has led and participated in multiple clinical trials involving advanced molecular tracers (e.g. 18F-FET, Ga-68 FAPI, PSMA, Y-90), and her recent publications reflect strong expertise in theranostics and quantitative imaging. Her current interest will be advancing low-dose, high-sensitivity imaging platforms and guiding clinical validation in patients through her dual focus on precision diagnostics and operational excellence.

Session:

Plenary 3
18 April 2026, 0915 - 1000hrs, NAK Auditorium, Academia

Presenting Title:

Theranostics - How Molecular Imaging is Shaping Healthcare
Theranostics—the combined use of molecular imaging and targeted therapy—is rapidly becoming a meaningful addition to clinical practice in Singapore. By using the same target for both imaging and treatment, theranostics enables precise patient selection, early assessment of treatment response, and more personalised care pathways. Within SGH and SingHealth, this approach has already supported clinical decision making in patients with neuroendocrine tumours and metastatic prostate cancer, improving symptom control, and offering options for patients who previously had limited alternatives.

Across Singapore’s public healthcare system, interest in theranostics is growing as we move toward more integrated and data enabled models of care. Radiopharmaceutical innovation, expanding PET access, and multidisciplinary collaboration are creating practical opportunities for broader adoption. At the same time, operational considerations familiar to local clinicians remain central: production capacity, regulatory approvals, supply chain logistics, and alignment with national funding and reimbursement frameworks. As demand increases, ensuring sustainable and equitable access across institutions will be key.

This lecture will review the clinical principles underpinning theranostics. It will also examine system level factors—such as manpower training, supply chain resilience, and the integration of analytics and AI—to support future expansion within the Singapore healthcare environment.

As Singapore advances toward more personalised, efficient, and seamless care, theranostics represents a timely opportunity to strengthen how we diagnose, treat, and monitor disease. Its continued development will help clinicians deliver more precise and patient centred care, while supporting the broader national goals of healthcare transformation.

Return to Speakers >